Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1993 Mar;48(3):260–263. doi: 10.1136/thx.48.3.260

Failure of frusemide to increase production of prostaglandin E2 in human nasal mucosa in vivo.

J Mullol 1, I Ramis 1, J Prat 1, J Roselló-Catafau 1, A Xaubet 1, C Piera 1, E Gelpí 1, C Picado 1
PMCID: PMC464364  PMID: 8497826

Abstract

BACKGROUND: It has been suggested that inhaled frusemide protects subjects with asthma against bronchoconstriction by enhancing the synthesis of prostaglandin E2 (PGE2). To evaluate this hypothesis the effect of frusemide on PGE2 production from nasal mucosa was studied. METHODS: Two main arachidonic acid metabolites produced by epithelial cells, PGE2 and 15-hydroxy 5,8,11,13-eicosatetraenoic acid (15-HETE), were measured by radioimmunoassay in nasal secretions obtained by nasal lavages with saline. Eleven healthy volunteers were randomly assigned to two study days, one week apart, in a double blind crossover study. Nasal instillation with three increasing doses of frusemide (5, 10, and 20 mg) or placebo was carried out at intervals of 15 minutes. Nasal lavages were performed immediately before nasal instillations and 15, 30, and 60 minutes after the last instillation. RESULTS: Baseline concentrations of 15-HETE were at least six times higher than PGE2. No differences between frusemide and placebo were detected either on PGE2 or 15-HETE release. CONCLUSIONS: The findings do not support the hypothesis that the antiasthmatic effect of frusemide may be due to increased synthesis of PGE2 or release in the respiratory mucosa.

Full text

PDF
260

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson S. D., He W., Temple D. M. Inhibition by furosemide of inflammatory mediators from lung fragments. N Engl J Med. 1991 Jan 10;324(2):131–131. doi: 10.1056/NEJM199101103240218. [DOI] [PubMed] [Google Scholar]
  2. Ballou L., Cohen R. E., Ballou C. E. Saccharomyces cerevisiae mutants that make mannoproteins with a truncated carbohydrate outer chain. J Biol Chem. 1980 Jun 25;255(12):5986–5991. [PubMed] [Google Scholar]
  3. Ben-Dov I., Bar-Yishay E., Godfrey S. Heterogeneity in the response of asthmatic patients to pre-exercise treatment with cromolyn sodium. Am Rev Respir Dis. 1983 Jan;127(1):113–116. doi: 10.1164/arrd.1983.127.1.113. [DOI] [PubMed] [Google Scholar]
  4. Bianco S., Pieroni M. G., Refini R. M., Rottoli L., Sestini P. Protective effect of inhaled furosemide on allergen-induced early and late asthmatic reactions. N Engl J Med. 1989 Oct 19;321(16):1069–1073. doi: 10.1056/NEJM198910193211602. [DOI] [PubMed] [Google Scholar]
  5. Bianco S., Vaghi A., Robuschi M., Pasargiklian M. Prevention of exercise-induced bronchoconstriction by inhaled frusemide. Lancet. 1988 Jul 30;2(8605):252–255. doi: 10.1016/s0140-6736(88)92540-8. [DOI] [PubMed] [Google Scholar]
  6. Domingo C., Roig J., Planas F., Bechini J., Tenesa M., Morera J. Radiographic appearance of nosocomial legionnaires' disease after erythromycin treatment. Thorax. 1991 Sep;46(9):663–666. doi: 10.1136/thx.46.9.663. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Henke D., Danilowicz R. M., Curtis J. F., Boucher R. C., Eling T. E. Metabolism of arachidonic acid by human nasal and bronchial epithelial cells. Arch Biochem Biophys. 1988 Dec;267(2):426–436. doi: 10.1016/0003-9861(88)90048-3. [DOI] [PubMed] [Google Scholar]
  8. Knox A. J., Ajao P. Effect of frusemide on airway smooth muscle contractility in vitro. Thorax. 1990 Nov;45(11):856–859. doi: 10.1136/thx.45.11.856. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Marom Z., Shelhamer J. H., Sun F., Kaliner M. Human airway monohydroxyeicosatetraenoic acid generation and mucus release. J Clin Invest. 1983 Jul;72(1):122–127. doi: 10.1172/JCI110949. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Miyanoshita A., Terada M., Endou H. Furosemide directly stimulates prostaglandin E2 production in the thick ascending limb of Henle's loop. J Pharmacol Exp Ther. 1989 Dec;251(3):1155–1159. [PubMed] [Google Scholar]
  11. Naclerio R. M., Meier H. L., Kagey-Sobotka A., Adkinson N. F., Jr, Meyers D. A., Norman P. S., Lichtenstein L. M. Mediator release after nasal airway challenge with allergen. Am Rev Respir Dis. 1983 Oct;128(4):597–602. doi: 10.1164/arrd.1983.128.4.597. [DOI] [PubMed] [Google Scholar]
  12. Nichol G. M., Alton E. W., Nix A., Geddes D. M., Chung K. F., Barnes P. J. Effect of inhaled furosemide on metabisulfite- and methacholine-induced bronchoconstriction and nasal potential difference in asthmatic subjects. Am Rev Respir Dis. 1990 Sep;142(3):576–580. doi: 10.1164/ajrccm/142.3.576. [DOI] [PubMed] [Google Scholar]
  13. Pepys J., Hargreave F. E., Chan M., McCarthy D. S. Inhibitory effects of disodium cromoglycate on allergen-inhalation tests. Lancet. 1968 Jul 20;2(7560):134–137. doi: 10.1016/s0140-6736(68)90419-4. [DOI] [PubMed] [Google Scholar]
  14. Picado C., Ramis I., Rosellò J., Prat J., Bulbena O., Plaza V., Montserrat J. M., Gelpí E. Release of peptide leukotriene into nasal secretions after local instillation of aspirin in aspirin-sensitive asthmatic patients. Am Rev Respir Dis. 1992 Jan;145(1):65–69. doi: 10.1164/ajrccm/145.1.65. [DOI] [PubMed] [Google Scholar]
  15. Polosa R., Lau L. C., Holgate S. T. Inhibition of adenosine 5'-monophosphate- and methacholine-induced bronchoconstriction in asthma by inhaled frusemide. Eur Respir J. 1990 Jun;3(6):665–672. [PubMed] [Google Scholar]
  16. Ramis I., Catafau J. R., Serra J., Bulbena O., Picado C., Gelpi E. In vivo release of 15-HETE and other arachidonic acid metabolites in nasal secretions during early allergic reactions. Prostaglandins. 1991 Nov;42(5):411–420. doi: 10.1016/0090-6980(91)90032-b. [DOI] [PubMed] [Google Scholar]
  17. Ramis I., Catafau J. R., Serra J., Bulbena O., Picado C., Gelpi E. In vivo release of 15-HETE and other arachidonic acid metabolites in nasal secretions during early allergic reactions. Prostaglandins. 1991 Nov;42(5):411–420. doi: 10.1016/0090-6980(91)90032-b. [DOI] [PubMed] [Google Scholar]
  18. Ramis I., Roselló-Catafau J., Artigot M., Bulbena O., Picado C., Gelpí E. Simultaneous reversed-phase extraction of lipoxygenase and cyclooxygenase metabolites of arachidonic acid in nasal secretions: methodological aspects. J Chromatogr. 1990 Nov 16;532(2):217–225. doi: 10.1016/s0378-4347(00)83773-1. [DOI] [PubMed] [Google Scholar]
  19. Ramis I., Roselló-Catafau J., Bulbena O., Picado C., Gelpi E. 15-Hydroxyeicosatetraenoic acid as a major eicosanoid in nasal secretions: assay by high-performance liquid chromatographic-radioimmunoassay and gas chromatographic-mass spectrometric procedures. J Chromatogr. 1989 Nov 24;496(2):416–422. doi: 10.1016/s0378-4347(00)82589-x. [DOI] [PubMed] [Google Scholar]
  20. Ramis I., Serra J., Roselló J., Picado C., Gelpi E., Vidal A. A. PGE2 and PGF2 alpha in the nasal lavage fluid from healthy subjects: methodological aspects. Prostaglandins Leukot Essent Fatty Acids. 1988 Nov;34(2):109–112. doi: 10.1016/0952-3278(88)90071-3. [DOI] [PubMed] [Google Scholar]
  21. Robuschi M., Gambaro G., Spagnotto S., Vaghi A., Bianco S. Inhaled frusemide is highly effective in preventing ultrasonically nebulised water bronchoconstriction. Pulm Pharmacol. 1989;1(4):187–191. doi: 10.1016/s0952-0600(89)80016-x. [DOI] [PubMed] [Google Scholar]
  22. Vanderhoek J. Y., Tare N. S., Bailey J. M., Goldstein A. L., Pluznik D. H. New role for 15-hydroxyeicosatetraenoic acid. Activator of leukotriene biosynthesis in PT-18 mast/basophil cells. J Biol Chem. 1982 Oct 25;257(20):12191–12195. [PubMed] [Google Scholar]
  23. Welsh M. J. Inhibition of chloride secretion by furosemide in canine tracheal epithelium. J Membr Biol. 1983;71(3):219–226. doi: 10.1007/BF01875463. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES